Skip to main content
Clinical Trials/NCT01938755
NCT01938755CompletedPhase 4

Hyperbaric Levobupivacaine for Spinal Anaesthesia

T.C. ORDU ÜNİVERSİTESİ1 site in 1 country73 target enrollmentStarted: June 2013Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
73
Locations
1
Primary Endpoint
degree of motor blockade

Study Overview

Brief Summary

Spinal anaesthesia also called spinal block or sub-arachnoid block (SAB), is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space, generally through a fine needle.

There is no generic hyperbaric form of levobupivacaine currently available so we aimed in this study that to find the appropriate concentration of the levobupivacaine which achieves unilateral spinal anesthesia. The potential benefits of this type of anesthesia are less motor blockade and urinary retention, decrease in hospital stay. Therefore, it seems to be suitable for outpatient anesthesia.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Approval to participate in the study and spinal anesthesia
  • American society of anesthesia (ASA) I,II physical status
  • Scheduled for lower extremity surgery

Exclusion Criteria

  • Refuse to participate in the study
  • American society of anesthesia (ASA)III, IV physical status
  • Hypersensitivity to local anesthetics
  • Emergency surgery
  • Chronic pain treatment
  • Peripheral neuropathy
  • Severe systemic disease

Arms & Interventions

levobupivacaine I

Experimental

group that was administered levobupivacaine plus 60mg dextrose

Intervention: levobupivacaine (Drug)

levobupivacaine II

Experimental

group that was administered levobupivacaine plus 80 mg dextrose

Intervention: levobupivacaine (Drug)

levobupivacaine III

Experimental

group that was administered levobupivacaine plus 100 mg dextrose

Intervention: levobupivacaine (Drug)

Outcomes

Primary Outcomes

degree of motor blockade

Time Frame: until dissolve of motor blockade

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
T.C. ORDU ÜNİVERSİTESİ
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

özgür yağan

Özgür Yağan

T.C. ORDU ÜNİVERSİTESİ

Study Sites (1)

Loading locations...

Similar Trials